AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

Dr. Lal PathLabs posts Q4 FY24 consolidated PAT at Rs. 84.5 Cr

The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

ORACEA is a trademark of Galderma Holdings, S.A.

Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals

Eugia Pharma Specialities receives 7 observations from USFDA for Unit II

Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets

Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA